DiscoverThe Spot Check
The Spot Check
Claim Ownership

The Spot Check

Author: Dermsquared

Subscribed: 3Played: 50
Share

Description

Introducing The Spot Check, the latest addition to the lineup of esteemed dermatology podcasts from Dermsquared™. In this exciting new venture for physician assistants and nurse practitioners, periodic timely episodes spotlight key special events, upcoming conferences, professional opportunities, and more. If you’re a PA or NP, The Spot Check is your go-to resource for staying informed, connected, and inspired. Tune in to stay ahead of the curve and make the most of important happenings in dermatology.

26 Episodes
Reverse
Patients with chronic spontaneous urticaria (CSU) can spend months searching for an explanation, moving between urgent care, primary care, and allergy appointments without getting much closer to relief. By the time they reach dermatology, they may not have a single hive to show for it. In this episode of The Spot Check, Jamie Restivo, PA-C, talks with David Seiter, FNP-C, about breaking what Restivo calls the “CSU shuffle” and the role dermatology clinicians can play in getting patients treated sooner.  Much of that begins with a careful history rather than another round of testing. Seiter explains how he distinguishes CSU from inducible urticaria, the history-based clues that point to something other than CSU, such as urticarial vasculitis or angioedema without hives, and why an exhaustive search for triggers can sometimes delay care. Once the diagnosis is established, the conversation turns to treatment, including what the updated urticaria guidelines recommend for second-generation H1-antihistamines, how quickly doses can be increased, how long to wait before considering escalation, and why moving to advanced therapy means adding on rather than replacing antihistamines.  With three targeted therapies now available, clinicians have more to consider than efficacy alone. Restivo and Seiter discuss omalizumab, dupilumab, and the oral BTK inhibitor remibrutinib, comparing their mechanisms, expected response times, and safety considerations. They also look at the practical side of treatment selection, from needle preferences and twice-daily dosing to travel, storage, and the routines patients can realistically maintain.  Follow-up is just as important. Seiter describes how he sets expectations for improvement, checks on patients after starting systemic therapy, and approaches tapering antihistamines once symptoms are consistently controlled. His larger point is that dermatology clinicians are well positioned to manage CSU, and for many patients, another referral or another test is not what they need. 
In vitiligo, the return of pigment and the end of the disease are two different things. A patient can repigment well and still develop new patches later, and that possibility shapes nearly every treatment conversation that follows. In this episode of The Spot Check, Jamie Restivo, PA-C, talks with Nada M. Elbuluk, MD, about managing a chronic autoimmune disease whose most visible improvements arrive slowly.  Much of that work begins at the first visit. Dr Elbuluk describes how she frames the diagnosis for patients, taking care to remove any sense that they caused it, and how she distinguishes segmental from nonsegmental disease. She also discusses the clinical signs that suggest vitiligo is actively progressing, among them confetti depigmentation and Koebnerization, and what positive thyroid antibodies can signal even when thyroid function is normal.  Topical therapies can quiet the immune attack, but they do not always get melanocytes working again. That gap is where narrowband UVB earns its place, and Dr Elbuluk explains how she combines the two and how the distribution of disease decides between a full-body booth and targeted light. Anatomy matters as well; the face tends to respond, while the fingers, toes, and other sites with few melanocytes to draw on are another matter.  Phototherapy two to three times a week asks a great deal of patients, and the trips to the office can become an obstacle of their own. Restivo and Dr Elbuluk discuss where home units fit, including why she sometimes starts patients in the office before they invest in a device, and how she thinks about tapering once pigment has returned or response has plateaued. Toward the end of the episode, she highlights a reality often obscured by the "cosmetic" label: vitiligo dictates daily life, quietly deciding what patients wear, where they go, and which moments they skip altogether.
For years, dermatology has become increasingly precise in the therapies it can offer. The harder question is whether we can become just as precise in choosing among them. In this episode of The Spot Check, Jamie Restivo, PA-C, is joined by Brad Glick, DO, MPH, to explore what precision medicine looks like as dermatology begins moving beyond how disease appears on the surface and toward what may be happening biologically underneath it.  Clinicians may have several highly effective treatment classes available in inflammatory disease but still rely heavily on trial and error. Restivo and Dr Glick discuss how molecular and transcriptomic profiling may add another layer of information to the clinical picture, particularly in psoriasis and atopic dermatitis, helping clinicians think more intentionally about which therapeutic class may be the better fit for the individual patient in front of them. Just as important, Dr Glick is clear that these tools do not replace clinical judgment; they sit alongside comorbidities, treatment history, patient preference, access, and everything else that already shapes a treatment decision.  The conversation also gets into what repeated treatment cycling costs. A therapy that does not work means more than another prescription. It can mean months lost, another prior authorization, another conversation about switching, and another round of frustration for both patient and clinician. Dr Glick walks through how objective biomarker data may help narrow that process, from the biologic-naive patient to someone who has already experienced primary or secondary treatment failure, while also giving clinicians additional information to bring into access and payer discussions.  What emerges is a larger change in how inflammatory skin disease may eventually be understood. Rather than stopping at phenotype alone, Dr Glick describes a future in which clinicians increasingly consider both what they see and the underlying biology driving it. The tools are still evolving, and they are not perfect. But the direction is clear: less random selection, more information at the point of care, and a more individualized way of matching patients with the therapies most likely to make sense for them.   
A biopsy is only as useful as the tissue you send, and information that travels with it. In this episode of The Spot Check, Jamie Restivo, PA-C, is joined by dermatologist and dermatopathologist John Griffin, MD, for a practical look at what happens between the clinic and the microscope, and how more thoughtful biopsy technique can lead to clearer answers when the diagnosis is anything but straightforward.  Dr. Griffin starts with a deceptively simple question: where is the pathology? Thinking about whether a process lives in the epidermis, dermis, or deeper in the fat can change the type and depth of biopsy needed before the blade ever touches the skin. From autoimmune blistering disease and connective tissue disorders to vasculitis and alopecia, they work through the details that matter, including lesion age, biopsy depth, specimen selection, and occasions when one sample may tell a very different story.  They also take on some of the diagnoses that can be particularly difficult to capture. For suspected cutaneous T-cell lymphoma, Dr Griffin explains why multiple biopsies may be more important than choosing between a broad shave and punch alone, recent topical steroid use that can obscure the lymphocytes needed for diagnosis, and the reasons a more raised or indurated lesion may offer a better target. The conversation also moves through pigmented lesions and recurrent pigment within a scar, where knowing the history of a prior biopsy can materially change how the dermatopathologist interprets what is under the microscope.  But the larger lesson goes beyond biopsy technique. Dr. Griffin asks clinicians to think of the pathology requisition as a consultation, not a one-way lab order. A photograph, a precise description, a meaningful differential, or a phone call when the report does not fit the patient can all add context that histology alone cannot provide. As he puts it, the clinician sees patterns on the patient, and the pathologist sees patterns under the microscope. Getting to the right diagnosis often depends on making sure those two pictures line up. 
For years, topical nonsteroidals largely occupied a supporting role in inflammatory skin disease—the option between steroid courses or when steroids simply weren’t a good fit. Tapinarof has helped change that calculus.  In this episode of The Spot Check, Jamie Restivo, PA-C, sits down with dermatologist Nick Brownstone, MD, to look beyond the “steroid-sparing” label and into how he actually thinks about tapinarof in psoriasis and atopic dermatitis. They begin with its aryl hydrocarbon receptor mechanism and what Dr Brownstone calls its “triple threat”: modulation of inflammatory pathways, effects on the skin barrier, and antioxidant activity. From there, the conversation moves quickly into the decisions that matter once a prescription leaves the exam room.  What exactly are those follicular events described in the psoriasis trials, and should clinicians think of them as traditional infectious folliculitis? Why were contact dermatitis rates lower in the atopic dermatitis studies than might be expected? How does burning and stinging compare with older nonsteroidal topicals? And when one of these reactions does occur, what does it actually mean for treatment?  Perhaps most useful is the discussion of what happens after patients get clear. Dr Brownstone and Jamie unpack the treatment-free intervals observed in psoriasis and atopic dermatitis and how a treat-until-clear, stop, monitor, and restart-with-flare approach can change the conversation around chronic topical therapy. They close with the details that often determine whether any regimen succeeds at all: a thin layer, once-daily application, choosing a time that fits the patient’s routine, and counseling clearly enough that patients know what to expect without making treatment more complicated than it needs to be. 
loading
Comments